ArticleDrug delivery2020
Erythrocyte-mimicking paclitaxel nanoparticles for improving biodistributions of hydrophobic drugs to enhance antitumor efficacy.
Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- From Nature to Nanomedicine: Engineered Plant-Derived Nanovesicles for Skin Disease.International journal of nanomedicine · 2026Review
- Hydrogel-based systems with nanoparticle and microencapsulation for food preservation: Preparation, characterization, and application.Food chemistry: X · 2026Review
- Research Progress of Multicomponent Co-Loaded Nanomedicine Delivery Systems for Tumor Immunotherapy.International journal of nanomedicine · 2026Review
- Engineered Extracellular Vesicles for Targeted Paclitaxel Delivery in Cancer Therapy: Advances, Challenges, and Prospects.Cellular and molecular bioengineering · 2025Review
- Advances in cell membrane-based biomimetic nanodelivery systems for natural products.Drug delivery · 2024Review
- Review
- Engineered and Mimicked Extracellular Nanovesicles for Therapeutic Delivery.Nanomaterials (Basel, Switzerland) · 2024Review
- Erythrocytes Nanoparticle Delivery: A Boon for Targeting Tumor.Advanced pharmaceutical bulletin · 2024Review
- Red blood cells: a potential delivery system.Journal of nanobiotechnology · 2023Review
- Phytochemicals and Cancer Treatment: Cell-Derived and Biomimetic Vesicles as Promising Carriers.Pharmaceutics · 2023Review
- Research update on cell membrane camouflaged nanoparticles for cancer therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Progress in the development of stabilization strategies for nanocrystal preparations.Drug delivery · 2021Review
- A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.Scientific reports · 2021Article
- Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives.Regenerative biomaterials · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent decades have witnessed several nanocrystal-based hydrophobic drug formulations because of their excellent performance in improving drug loading and controlling drug release as mediate drug forms in tablets or capsules. However, the intravenous administration of drug nanocrystals was usually hampered by their hydrophobic surface properties, causing short half-life time in circulation and low drug distribution in tumor. Here, we proposed to enclose nanocrystals (NC) of hydrophobic drug, such as paclitaxel (PTX) into erythrocyte membrane (EM). By a series of formulation optimizations, spherical PTX nanoparticles (PN) with the particle size of around 280 nm were successfully cloaked in erythrocyte membrane, resulting in a PTX-NP-EM (PNM) system. The PNM could achieve high drug loading of PTX (>60%) and stabilize the particle size significantly compared to PN alone. Besides, the fluorescence-labeling PNM presented better tumor cell uptake, stronger cytotoxicity, and higher drug accumulation in tumor compared to PN. Finally, the PNM was found to be the most effective against tumor growth among all PTX formulations in tumor-bearing mice models, with much lower system toxicity than control formulation. In general, the PNM system with high drug-loading as well as superior bio-distributions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.